



January 2025 Monthly Report

Returns 31-Dec-12 to 31-Jan-25

	Norse Capital	All Ords Accum	Outperformance	Small Ords Accum	Outperformance
Inception	532.75%	204.98%	327.77%	101.57%	431.18%
Inception per annum	16.48%	9.66%	6.82%	5.97%	10.51%
CY2025 (ytd)	2.89%	4.38%	-1.49%	4.59%	-1.69%
CY2024	45.23%	11.44%	33.78%	8.36%	36.87%
CY2023	17.73%	12.98%	4.75%	7.82%	9.90%
CY2022	-30.79%	-2.96%	-27.83%	-18.38%	-12.41%
CY2021	16.86%	17.74%	-0.88%	16.90%	-0.04%
CY2020	26.36%	3.64%	22.73%	9.21%	17.15%
CY2019	43.44%	24.06%	19.38%	21.36%	22.08%
CY2018	7.46%	-3.53%	10.99%	-8.67%	16.13%
CY2017	15.55%	12.47%	3.08%	20.02%	-4.46%
CY2016	9.31%	11.65%	-2.33%	13.18%	-3.87%
CY2015	36.80%	3.78%	33.02%	10.16%	26.65%
CY2014	10.81%	5.02%	5.79%	-3.81%	14.62%
CY2013	19.24%	19.66%	-0.41%	-0.76%	20.00%
1m	2.89%	4.38%	-1.49%	4.59%	-1.69%
3m	13.59%	4.66%	8.93%	2.70%	10.89%
6m	25.37%	7.49%	17.88%	6.57%	18.80%
1y	45.20%	15.10%	30.10%	12.32%	32.88%
2y pa	31.50%	11.10%	20.39%	7.08%	24.42%
3y pa	9.57%	10.92%	-1.35%	3.10%	6.47%
5y pa	10.81%	8.24%	2.56%	4.25%	6.56%
7y pa	15.37%	9.33%	6.04%	5.12%	10.25%
10y pa	16.60%	8.94%	7.66%	7.66%	8.94%
12y pa	16.38%	9.28%	7.10%	5.65%	10.73%
Sharpe Ratio	0.98	0.61	1.61x	0.32	3.10x
Sortino Ratio	1.66	0.86	1.93x	0.45	3.71x
Annualised standard deviation	14.79%	13.57%		16.61%	
Highest monthly return	11.91%	10.16%		14.27%	
Largest monthly loss	-10.61%	-20.94%		-22.38%	
Largest drawdown	-36.68%	-27.33%		-29.11%	
% positive months	69.66%	65.52%		57.93%	

A positive start to 2025 at +2.9% although underperforming the Australian indices with the All Ords at +4.4% and the Small Ords at

+4.6%. Performance was ahead of the US indices with the S&P 500 +2.7% and the Nasdaq +1.6%. In hindsight not perfect timing to take risk off the table by dropping our exposure to ~70% at the end of 2024; market timing is obviously not my forte.

The biggest loss for the month came from RUL with the shares down -9.2%. No significant news, the shares paring back from a run above \$3 ahead of results later this month.

A drop in AAPL too with the shares down -5.8% in January. The company beat on revenues (+4%) and EPS (\$2.40 vs \$2.35 expected) but iPhone revenue missed and China sales declined -11.1%. Services remained a bright spot at +14%. AI has yet to be completely rolled out onto its iPhone platform – the question remains whether this can drive iPhone upgrades when that occurs. Interestingly AAPL shares performed relatively well on the DeepSeek downdraft as Apple has not spent massively on AI capex and should theoretically benefit from cheaper AI inference, particularly at the edge. We have partial put spread protection on half our Apple shares near current levels.

Shorts and hedges cost us ~-0.6% and the ~+0.4% rise in the Aud-Usd cost another ~-0.3%.

Our biggest positive contribution came again from PME. The shares rose +11.3%, aided by the announcement of a \$33m, 9-year contract with the University of Kentucky and followed up (post month-end) with a \$53m, 7-year contract with BayCare. A positive cadence of contract announcements (following 2 in December) ahead of results later this month.


TLX shares added +19.2% as they exceeded prior FY24 guidance (US \$517m vs US\$500m at the midpoint of guidance), representing a +55% increase. Telix also received European approval for its prostate cancer PET imaging agent, Illuccix.

Our enterprise software basket added +1.1% to the portfolio, thanks to CRWD up +16.3% and ZS +12.3%. Software application companies performed well in the DeepSeek pullback; again, cheaper inference should benefit application software. Our hedge of 40% of our CRWD position was financed by selling \$400 calls which are currently in the money.

Portfolio Holdings:

Cash: 15.0% (AUD and USD)
AUD-USD currency exposure: 34.5%
Longs: 91.7%
Shorts: -7.4%
Options delta: -12.3%
Net exposure: 72.0%
Top 5 equities (alphabetical): AAPL, PME, RMD, RUL, TTD

Slightly longer net exposure as our put option deltas decline. Option vols as represented by the VIX are a few notches higher, currently ~16.5 vs the ~14 and below levels from most of 2024 but remain below historical higher levels. Arguably even cheap gamma given the market volatility in the first 2 weeks of Trump's presidency; whether we continue to see elevated market movements either way...



Performance/Risk Ratios

